Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

Sarah Tasian

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

Updates in ALL: Incorporating Immunotherapy in Frontline Management

Talha Badar

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Vanderbilt University Medical Center (VUMC)

A. Jallouk

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

Blinatumomab in First-Line ALL - Safety, Efficacy, and Experience

Salman Fazal

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Fred Hutchinson Cancer Center

R. Cassaday

Understanding CRISPR and Gene Editing in the Treatment of Heme Malig…

UChicago Medicine

A. Cooper

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

Incorporating Blinatumomab and Inotuzumab Into 1L ALL Treatment

MyCancerHaven

R. Vij, N. Short

The Importance of MRD in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Ravandi

Treating Adults With Newly Diagnosed ALL

MyCancerHaven

R. Vij, A. Patel

Treating Adult B-ALL: CAR-T vs. Bispecifics vs. Monoclonals

Marlise R. Luskin

Chronic GvHD: Main Complications After ASCT

Steven Pavletic